'Long Covid Research Initiative' and Polybio funded to research viral persistence and antiviral treatments

Discussion in 'Long Covid news' started by SNT Gatchaman, Jul 19, 2022.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,761
    Location:
    Aotearoa New Zealand
    Hutan, rvallee, RedFox and 3 others like this.
  2. Sly Saint

    Sly Saint Senior Member (Voting Rights)

    Messages:
    9,922
    Location:
    UK
    Merged thread

    Dr. Amy Proal, Ph.D - Transforming Diagnosis & Treatment Of Complex Chronic Inflammatory Conditions


    https://www.youtube.com/watch?v=TkZBXCFqRts


     
    Last edited by a moderator: Oct 9, 2022
  3. Laurie P

    Laurie P Senior Member (Voting Rights)

    Messages:
    209
    Location:
    New England, USA
    rvallee, Trish, Hutan and 1 other person like this.
  4. Trish

    Trish Moderator Staff Member

    Messages:
    55,414
    Location:
    UK
  5. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    5,761
    Location:
    Aotearoa New Zealand
    I'm especially interested in the imaging-related projects —
    • Use of total-body PET imaging to identify deep-tissue SARS-CoV-2 viral reservoirs and T cell responses in patients with Long COVID
    • Evaluation of tissue fibrin accumulation and perfusion in Long COVID, via Fibrin-PET imaging & peripheral blood analysis
    • Innate neuroimmunity and cognitive function in Long COVID
    • Ultrahigh resolution 7-Tesla imaging of structural abnormalities, cerebrospinal fluid flow, and other symptom mechanisms in patients with infection-associated chronic disease
     
  6. Jaybee00

    Jaybee00 Senior Member (Voting Rights)

    Messages:
    2,177
    https://twitter.com/user/status/1709700433315328109


    Confirmed by leading Long Covid researcher @microbeminded2: 1. Long Covid is new & novel 2. Long Covid’s major driver & area of research: SARS persistence 3. ME & LC are not =. Both can be viral persistence, origins/pathogen activity biologically different

    Evidence for this Amy Proal claim?

    “Leading Long Covid researcher” who has no lab and no academic affiliation.
     
    Hutan, RedFox, Wyva and 2 others like this.
  7. Jaybee00

    Jaybee00 Senior Member (Voting Rights)

    Messages:
    2,177
    https://twitter.com/user/status/1719695012835770565


    15 million to Polybio. IMO this will be a waste.

    “The focus will be the continued study and treatment of #SARS-CoV-2 persistence as a driver of LongCovid.”

    For which there is no convincing evidence…..
     
    Trish, RedFox and Woozy like this.
  8. Jaybee00

    Jaybee00 Senior Member (Voting Rights)

    Messages:
    2,177
    BS from AP. She knows the mechanism!! Prey tell.

    "Mechanisms underlying Long COVID are not a mystery," says Dr. Amy Proal PhD, PolyBio's Chief Scientific Officer. "The persistence of SARS-CoV-2 in tissue is a major target for rapid #research and clinical trials."
     
  9. Woozy

    Woozy Established Member (Voting Rights)

    Messages:
    31
    OMG 15 million. god these scientists are onto a good thing. In my next life I will become a scientist not a concert pianist (maybe not as I like being a concert pianist lol)
     
    obeat likes this.
  10. Solstice

    Solstice Senior Member (Voting Rights)

    Messages:
    1,216
    Happy about this actually. I do feel they might be on to something and their researchers will at least do their due diligence.
     
    EzzieD, livinglighter and Trish like this.
  11. Sean

    Sean Moderator Staff Member

    Messages:
    8,064
    Location:
    Australia
    If the study can provide definitive answers either way then it is probably worth doing.
     
    Hutan, Trish, V.R.T. and 5 others like this.
  12. EndME

    EndME Senior Member (Voting Rights)

    Messages:
    1,204
    Hutan, Solstice and Trish like this.
  13. forestglip

    forestglip Senior Member (Voting Rights)

    Messages:
    874
    Total-body PET imaging to identify deep-tissue SARS-CoV-2 reservoirs in Long COVID

    "This study is the first in the world using advanced imaging technologies to identify deep tissue SARS-CoV-2 reservoirs in Long Covid study participants.

    Specifically the team is using longitudinal ImmunoPET-CT imaging of radiolabeled SARS-CoV-2-specific monoclonal antibodies (mAbs) to identify SARS-CoV-2 tissue reservoirs in individuals with Long COVID.

    Tissue biopsy samples from the lymph node and gut are also being collected from Long COVID study participants undergoing imaging. These tissue samples are being analyzed for SARS-CoV-2 RNA, spike, and nucleocapsid proteins, other chronic viruses (e.g., Epstein-Barr virus and cytomegalovirus), and cellular immune responses. Data collected on the tissue samples will be correlated with the imaging data, so that potential viral reservoirs in study participants can be validated by overlapping methods."

    "In this project, the team is taking a monoclonal antibody (a medication that specifically targets the SARS-CoV-2 spike protein wherever it might be in the body) and “tagging” it with a tiny amount of radioactivity (called radiotracers). They then safely inject the tagged monoclonal antibody into participants with Long COVID. The tagged monoclonal antibody diffuses throughout the participants’ bodies, and if it encounters the SARS-CoV-2 spike protein, it will selectively bind it. Wherever this binding occurs its tagged radiotracer will become trapped and rapidly decay. This can be detected in 3-dimensions by the PET scanner’s ultra-sensitive camera. The PET scanner camera documents the location of these tagged antibodies, which can be used to infer the location of the SARS-CoV-2 spike protein in the patients’ tissue. In other words, the PET scanner is able to triangulate the specific location of any SARS-CoV-2 viral reservoir sites within the body."

    Discussion on Phoenix Rising
     
    Yann04, Trish, Hutan and 2 others like this.

Share This Page